These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 25460146)
21. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related]
23. Expression of CD133 in synovial sarcoma. Terry J; Nielsen T Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721 [TBL] [Abstract][Full Text] [Related]
24. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848 [TBL] [Abstract][Full Text] [Related]
25. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
26. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Swaminathan SK; Roger E; Toti U; Niu L; Ohlfest JR; Panyam J J Control Release; 2013 Nov; 171(3):280-7. PubMed ID: 23871962 [TBL] [Abstract][Full Text] [Related]
27. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747 [TBL] [Abstract][Full Text] [Related]
28. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Le H; Zeng F; Xu L; Liu X; Huang Y Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862 [TBL] [Abstract][Full Text] [Related]
29. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372 [TBL] [Abstract][Full Text] [Related]
30. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727 [TBL] [Abstract][Full Text] [Related]
31. Biology and clinical implications of CD133(+) liver cancer stem cells. Ma S Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864 [TBL] [Abstract][Full Text] [Related]
32. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice]. Song WC; Fei XF; Dong J Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405 [TBL] [Abstract][Full Text] [Related]
33. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. Tirino V; Desiderio V; Paino F; De Rosa A; Papaccio F; Fazioli F; Pirozzi G; Papaccio G FASEB J; 2011 Jun; 25(6):2022-30. PubMed ID: 21385990 [TBL] [Abstract][Full Text] [Related]
34. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377 [TBL] [Abstract][Full Text] [Related]
35. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143 [TBL] [Abstract][Full Text] [Related]
36. Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Lo YL; Tu WC Chem Biol Interact; 2015 Dec; 242():13-23. PubMed ID: 26335193 [TBL] [Abstract][Full Text] [Related]
37. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo. Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787 [TBL] [Abstract][Full Text] [Related]
38. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800 [TBL] [Abstract][Full Text] [Related]
39. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Ma L; Lai D; Liu T; Cheng W; Guo L Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681 [TBL] [Abstract][Full Text] [Related]
40. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]